Seminar on hemochromatosis the 18^th of September

On the 18^th of September, Evry iGEM team organized a seminar on hemochromatosis on iron related diseases. The aim of this seminar is to present the latest scientific advances on thoses diseases and futur treatments. We also take this opportunity to present synthetic biology and our project in iGEM competition to both scientists and patients.

Day's agenda

Start time	Speaker	Subject
10:00	Gabriel Guillocheau	Opening speech
10:15	PHD-DR Gaël Nicolas	Iron homeostasis in mammals and its deregulation
11:00	PU-PH Pierre Brissot	Hemochromatosis: its diagnostic and its treatment
11:45	Break
12:00	Docteur Marie-Paule Roth	Link between HFE, hepcidin and BMP6
12:45	Lunch
14:15	Result questionnaire with patients participation
15::00	Nicolas Pollet	Microbiom studies
15:45	Break
16:00	iGEM EVRY team	A bacterial treatment for hemochromatosis
16:45	Gabriel Guillocheau	Closing speech

Report of the day

Gaël Nicolas: "Iron homeostasis in mammals and its deregulation"

Summary

Iron is necessary to living beings but potentially toxic, that is why homeostasis is required. In a human body there are 4g to 5g of iron, that is about a rusted nail. Iron is present as Fe2+ and Fe3+; as Fe3+ it is insoluble and thus must be degraded in Fe2+, but as Fe2+ it becomes highly toxic because it is a strong oxidant. Much of iron is located in the red blood cells. This explains why we associate iron with oxygen transport, but many other reactions imply iron.
In the 1930's, an experiment showed that iron was not excreted by the body: iron remains stocked in the body. We absorb 1mg to 2mg of iron daily in order to compensate 1mg to 2 mg of iron lost daily through the death of cells. The production of red blood cells uses 20mg of iron daily, but these 20mg exclusively come from the recycling process of old red blood cells by macrophages.
Hepcidin is a hormone that makes the level of iron in the serum decrease. Hepcidin is thus to iron approximatively what insulin is to glucose. Its deficiency is implied in almost all the forms of hemochromatosis. This hormone has three sulphur bridges, that makes it very difficult to synthesise.

Question/Answer

Q1: ....
A1: ...

Q2: ...
A2: ...

Pierre Brissot: "Hemochromatosis: its diagnostic and its treatment"

Summary

Hemochromatosis is a frequent genetical disease: in France one person over 300 is predisposed develop it. Indeed, it is a disease with an incomplete penetrance, what means that all the people who are homozygote will not develop the disease. Hemochromatosis is also a delayed disease because the symptoms are long to appear: hemochromatosis is long silent.
The first symptoms are chronic tiredness and rheumatism. As they are not very specific symptoms, 5 to 10 years often pass between their appearance and the diagnosis. The excess deposition of iron has serious consequences on the organs, and first of all on the liver. The liver is indeed the first barrier of the body against iron. The excess deposition of iron in the liver leads to its cirrhosis, and when the liver can stock no more iron, iron goes to the pancreas and the hearth.
The most usual genetic mutation causing hemochromatosis is a mutation of the “iron gene” on the chromosome 6, called C282Y homozygosity. This mutation drastically decrease the production of hepcidin. The genetic test should be done only after a blood test determining iron level. It is also possible to use MRI to see if the liver stocks iron.
Bloodletting forces the organism to use the iron stocks to renew the red blood cells. Bloodletting gives really good results, almost without any side effect, but it is not perfect: for example rheumatism remains. Moreover some patients can not get used to the bloodletting. Iron chelators (in oral treatment) can thus be an alternative to bloodletting, or at least complete bloodletting.

Question/Answer

Q1: ....
A1: ...

Q2: ...
A2: ...

Marie-Paule Roth: "Link between HFE, hepcidin and BMP6"

Here a little summary of the presentation

Question/Answer

Q1: ....
A1: ...

Q2: ...
A2: ...

Result questionnaire with patients participation

Summary

We learned three important informations with our survey.
Most patients are satisfied with bloodletting, and the more satisfied they are, the less they want another treatment. Despite this, they remain interested in a complementary treatment.
The most interested patients are the patients who would benefit the less from the bacterian treatment. Indeed this treatment would be most appropriate after the first phase of treatment, to help regulating iron absorption and diminishing the frequence of bloodletting.
Last but not least, our survey shows that a bacterian treatment would be a real help for working patients, who often have difficulties to leave their job to go to bloodletting.

Question/Answer

Q1: ....
A1: ...

Q2: ...
A2: ...

Nicolas Pollet: "Microbiom studies"

Summary

All the micro-organisms that live in (and on) the human body constitute our microbiome. There are 10 times more of them than our own cells, and the microbiome as an all has 1000 times more genes than us. The microbiome is a necessary part of our organism, so there is a large number of beneficial bacterias.
The microbiome is still relatively unknown. We know that it is very complex. The number of micro-organisms increases exponentially along the digestive system; the microbiome varies depending on the place of the body, but also depending on the topology. Our microbiome changes during our live too: for example during pregnancy. Last but not least, we all have different microbiome, but it seems that there are several bacterial patterns. As the microbiome play a role in some pathologies, these patterns may be a major research field.

Question/Answer

Q1: ....
A1: ...

Q2: ...
A2: ...

iGEM EVRY team: "A bacterial treatment for hemochromatosis"

Here a little summary of the presentation

Question/Answer

Q1: ....
A1: ...

Q2: ...
A2: ...

Ressenti de quelques intervenants

Site developped by Gabriel Guillocheau